Whalesbook
Jaise hi Novo Nordisk ke patents khatam hue, usi din Dr. Reddy's ne GLP-1 therapy segment mein entry maari hai Obeda ke saath. Matlab ab company direct diabetes aur weight loss ki jo popular medicines hain, unme competetion badhane wali hai. Aur bhai, ye launch toh India aur baaki countries mein ek zabardast price war shuru karne wala hai.
Ab is Obeda ki baat karein toh ye ₹4,200 per month mein milega aur iske 2 mg aur 4 mg wale doses hain. Ye weekly injection hai jo ek pre-filled disposable pen se lagti hai. Clinical trials ne confirm kiya hai ki ye original drug jitni hi effective aur safe hai, blood sugar control mein bhi same results dikhaye hain. Dr. Reddy's ka plan hai pehle saal 12 million pens launch karne ka aur jab patents worldwide expire honge toh 87 countries mein isko launch karne ka irada hai. Unhone patients ke liye 'SemaKare™' naam ka support program bhi shuru kiya hai taaki log aasani se treatment start kar sakein.
India mein toh bhai, semaglutide market mein poori bhid lag gayi hai. Jab se Novo Nordisk ke patents India mein expire hue hain, lagbhag 40 se zyada Indian drugmakers, jaise ki Sun Pharma, Zydus Lifesciences, Lupin, aur Mankind Pharma, apni versions laane ki tayyari mein hain. Is competition ki wajah se prices mein 60% se 70% tak ki girawat aane ki umeed hai. Socho, jahan diabetes se 101 million se zyada adults suffer kar rahe hain, wahan ye medicine ab bahut se logon ke liye accessible ho jayegi. Dr. Reddy's toh khud ki manufacturing kar raha hai is drug ki, toh supply ki tension nahi hogi.
Haan, thoda challenge bhi hai. Market share paane ke liye prices kam rakhne padenge, jisse profit margins par pressure aayega, ye generic companies ke liye common hai. Global expansion mein bhi regulatory approvals mein time lag sakta hai. Kuch log isko lifestyle reasons ke liye bhi use kar sakte hain, jisse side effects aur regulatory scrutiny ka risk hai. Lekin analysts abhi bhi positive hain. Dr. Reddy's ke strong pipeline aur North America ke bahar growth prospects ko dekh kar, inki target prices $16.90 se $17.00 ke aas paas chal rahi hain. Company ne pichle do saal se active drug ingredient aur formulation capacity mein kaafi investment kiya hai, toh woh supply demand ko handle karne ke liye ready hain.